Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

Genetic LAMP2 deficiency accelerates the age-associated formation of basal laminar deposits in the retina.

Notomi S, Ishihara K, Efstathiou NE, Lee JJ, Hisatomi T, Tachibana T, Konstantinou EK, Ueta T, Murakami Y, Maidana DE, Ikeda Y, Kume S, Terasaki H, Sonoda S, Blanz J, Young L, Sakamoto T, Sonoda KH, Saftig P, Ishibashi T, Miller JW, Kroemer G, Vavvas DG.

Proc Natl Acad Sci U S A. 2019 Nov 19;116(47):23724-23734. doi: 10.1073/pnas.1906643116. Epub 2019 Nov 7.

2.

Discovery of CDZ173 (Leniolisib), Representing a Structurally Novel Class of PI3K Delta-Selective Inhibitors.

Hoegenauer K, Soldermann N, Zécri F, Strang RS, Graveleau N, Wolf RM, Cooke NG, Smith AB, Hollingworth GJ, Blanz J, Gutmann S, Rummel G, Littlewood-Evans A, Burkhart C.

ACS Med Chem Lett. 2017 Aug 25;8(9):975-980. doi: 10.1021/acsmedchemlett.7b00293. eCollection 2017 Sep 14.

3.

Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson's disease.

Burbulla LF, Song P, Mazzulli JR, Zampese E, Wong YC, Jeon S, Santos DP, Blanz J, Obermaier CD, Strojny C, Savas JN, Kiskinis E, Zhuang X, Krüger R, Surmeier DJ, Krainc D.

Science. 2017 Sep 22;357(6357):1255-1261. doi: 10.1126/science.aam9080. Epub 2017 Sep 7.

4.

Long-term enzyme replacement therapy improves neurocognitive functioning and hippocampal synaptic plasticity in immune-tolerant alpha-mannosidosis mice.

Stroobants S, Damme M, Van der Jeugd A, Vermaercke B, Andersson C, Fogh J, Saftig P, Blanz J, D'Hooge R.

Neurobiol Dis. 2017 Oct;106:255-268. doi: 10.1016/j.nbd.2017.07.013. Epub 2017 Jul 15.

PMID:
28720484
5.

Peroxisomal dysfunctions cause lysosomal storage and axonal Kv1 channel redistribution in peripheral neuropathy.

Kleinecke S, Richert S, de Hoz L, Brügger B, Kungl T, Asadollahi E, Quintes S, Blanz J, McGonigal R, Naseri K, Sereda MW, Sachsenheimer T, Lüchtenborg C, Möbius W, Willison H, Baes M, Nave KA, Kassmann CM.

Elife. 2017 May 4;6. pii: e23332. doi: 10.7554/eLife.23332.

6.

Effect of an interactive cardiopulmonary resuscitation assist device with an automated external defibrillator synchronised with a ventilator on the CPR performance of emergency medical service staff: a randomised simulation study.

Nitzschke R, Doehn C, Kersten JF, Blanz J, Kalwa TJ, Scotti NA, Kubitz JC.

Scand J Trauma Resusc Emerg Med. 2017 Apr 4;25(1):36. doi: 10.1186/s13049-017-0379-8.

7.

Evaluation of relative MS response factors of drug metabolites for semi-quantitative assessment of chemical liabilities in drug discovery.

Blanz J, Williams G, Dayer J, Délémonté T, Gertsch W, Ramstein P, Aichholz R, Trunzer M, Pearson D.

J Mass Spectrom. 2017 Apr;52(4):210-217. doi: 10.1002/jms.3918.

PMID:
28152561
8.

Sequestration of cholesterol within the host late endocytic pathway restricts liver-stage Plasmodium development.

Petersen W, Stenzel W, Silvie O, Blanz J, Saftig P, Matuschewski K, Ingmundson A.

Mol Biol Cell. 2017 Mar 15;28(6):726-735. doi: 10.1091/mbc.E16-07-0531. Epub 2017 Jan 25.

9.

Increasing metabolic stability via the deuterium kinetic isotope effect: An example from a proline-amide-urea aminothiazole series of phosphatidylinositol-3 kinase alpha inhibitors.

Fairhurst RA, Caravatti G, Guagnano V, Aichholz R, Blanz J, Blasco F, Wipfli P, Fritsch C, Maira SM, Schnell C, Seiler FH.

Bioorg Med Chem Lett. 2016 Oct 1;26(19):4729-4734. doi: 10.1016/j.bmcl.2016.08.041. Epub 2016 Aug 17.

PMID:
27575470
10.

Discovery and Pharmacological Characterization of Novel Quinazoline-Based PI3K Delta-Selective Inhibitors.

Hoegenauer K, Soldermann N, Stauffer F, Furet P, Graveleau N, Smith AB, Hebach C, Hollingworth GJ, Lewis I, Gutmann S, Rummel G, Knapp M, Wolf RM, Blanz J, Feifel R, Burkhart C, Zécri F.

ACS Med Chem Lett. 2016 Jun 2;7(8):762-7. doi: 10.1021/acsmedchemlett.6b00119. eCollection 2016 Aug 11.

11.

Discovery of Imidazoquinolines as a Novel Class of Potent, Selective, and in Vivo Efficacious Cancer Osaka Thyroid (COT) Kinase Inhibitors.

Glatthar R, Stojanovic A, Troxler T, Mattes H, Möbitz H, Beerli R, Blanz J, Gassmann E, Drückes P, Fendrich G, Gutmann S, Martiny-Baron G, Spence F, Hornfeld J, Peel JE, Sparrer H.

J Med Chem. 2016 Aug 25;59(16):7544-60. doi: 10.1021/acs.jmedchem.6b00598. Epub 2016 Aug 17.

PMID:
27502541
12.

Characterization of the complex formed by β-glucocerebrosidase and the lysosomal integral membrane protein type-2.

Zunke F, Andresen L, Wesseler S, Groth J, Arnold P, Rothaug M, Mazzulli JR, Krainc D, Blanz J, Saftig P, Schwake M.

Proc Natl Acad Sci U S A. 2016 Apr 5;113(14):3791-6. doi: 10.1073/pnas.1514005113. Epub 2016 Mar 21.

13.

Parkinson's disease: acid-glucocerebrosidase activity and alpha-synuclein clearance.

Blanz J, Saftig P.

J Neurochem. 2016 Oct;139 Suppl 1:198-215. doi: 10.1111/jnc.13517. Epub 2016 Feb 10. Review.

14.

Chronic enzyme replacement therapy ameliorates neuropathology in alpha-mannosidosis mice.

Damme M, Stroobants S, Lüdemann M, Rothaug M, Lüllmann-Rauch R, Beck HC, Ericsson A, Andersson C, Fogh J, D'Hooge R, Saftig P, Blanz J.

Ann Clin Transl Neurol. 2015 Sep 19;2(11):987-1001. doi: 10.1002/acn3.245. eCollection 2015 Nov.

15.

Lysosome associated membrane proteins maintain pancreatic acinar cell homeostasis: LAMP-2 deficient mice develop pancreatitis.

Mareninova OA, Sendler M, Malla SR, Yakubov I, French SW, Tokhtaeva E, Vagin O, Oorschot V, Lüllmann-Rauch R, Blanz J, Dawson D, Klumperman J, Lerch MM, Mayerle J, Gukovsky I, Gukovskaya AS.

Cell Mol Gastroenterol Hepatol. 2015 Nov 1;1(6):678-694.

16.

Orally bioavailable Syk inhibitors with activity in a rat PK/PD model.

Thoma G, Veenstra S, Strang R, Blanz J, Vangrevelinghe E, Berghausen J, Lee CC, Zerwes HG.

Bioorg Med Chem Lett. 2015 Oct 15;25(20):4642-7. doi: 10.1016/j.bmcl.2015.08.037. Epub 2015 Aug 18.

PMID:
26320624
17.

Mannose 6-phosphate-independent Lysosomal Sorting of LIMP-2.

Blanz J, Zunke F, Markmann S, Damme M, Braulke T, Saftig P, Schwake M.

Traffic. 2015 Oct;16(10):1127-36. doi: 10.1111/tra.12313. Epub 2015 Sep 1.

18.

Identification and optimisation of 4,5-dihydrobenzo[1,2-d:3,4-d]bisthiazole and 4,5-dihydrothiazolo[4,5-h]quinazoline series of selective phosphatidylinositol-3 kinase alpha inhibitors.

Fairhurst RA, Gerspacher M, Imbach-Weese P, Mah R, Caravatti G, Furet P, Fritsch C, Schnell C, Blanz J, Blasco F, Desrayaud S, Guthy DA, Knapp M, Arz D, Wirth J, Roehn-Carnemolla E, Luu VH.

Bioorg Med Chem Lett. 2015 Sep 1;25(17):3575-81. doi: 10.1016/j.bmcl.2015.06.067. Epub 2015 Jun 26.

PMID:
26199119
19.

Micropreparative isolation and NMR structure elucidation of metabolites of the drug candidate 1-isopropyl-4-(4-isopropylphenyl)-6-(prop-2-yn-1-yloxy) quinazolin-2(1H)-one from rat bile and urine.

Blanz J, Délémonté T, Pearson D, Luneau A, Ritzau M, Gertsch W, Ramstein P, Dayer J, Desrayaud S, Braun E, Aichholz R.

J Chromatogr B Analyt Technol Biomed Life Sci. 2015 May 1;989:1-10. doi: 10.1016/j.jchromb.2015.02.044. Epub 2015 Mar 10.

PMID:
25797717
20.

LAMP-2 deficiency leads to hippocampal dysfunction but normal clearance of neuronal substrates of chaperone-mediated autophagy in a mouse model for Danon disease.

Rothaug M, Stroobants S, Schweizer M, Peters J, Zunke F, Allerding M, D'Hooge R, Saftig P, Blanz J.

Acta Neuropathol Commun. 2015 Jan 31;3:6. doi: 10.1186/s40478-014-0182-y.

21.

Discovery and profiling of a selective and efficacious Syk inhibitor.

Thoma G, Smith AB, van Eis MJ, Vangrevelinghe E, Blanz J, Aichholz R, Littlewood-Evans A, Lee CC, Liu H, Zerwes HG.

J Med Chem. 2015 Feb 26;58(4):1950-63. doi: 10.1021/jm5018863. Epub 2015 Feb 9.

PMID:
25633741
22.

Lysosomal integral membrane protein type-2 (LIMP-2/SCARB2) is a substrate of cathepsin-F, a cysteine protease mutated in type-B-Kufs-disease.

Peters J, Rittger A, Weisner R, Knabbe J, Zunke F, Rothaug M, Damme M, Berkovic SF, Blanz J, Saftig P, Schwake M.

Biochem Biophys Res Commun. 2015 Feb 13;457(3):334-40. doi: 10.1016/j.bbrc.2014.12.111. Epub 2015 Jan 7.

PMID:
25576872
23.

LIMP-2 expression is critical for β-glucocerebrosidase activity and α-synuclein clearance.

Rothaug M, Zunke F, Mazzulli JR, Schweizer M, Altmeppen H, Lüllmann-Rauch R, Kallemeijn WW, Gaspar P, Aerts JM, Glatzel M, Saftig P, Krainc D, Schwake M, Blanz J.

Proc Natl Acad Sci U S A. 2014 Oct 28;111(43):15573-8. doi: 10.1073/pnas.1405700111. Epub 2014 Oct 14.

24.

Syk inhibitors with high potency in presence of blood.

Thoma G, Blanz J, Bühlmayer P, Drückes P, Kittelmann M, Smith AB, van Eis M, Vangrevelinghe E, Zerwes HG, Che JJ, He X, Jin Y, Lee CC, Michellys PY, Uno T, Liu H.

Bioorg Med Chem Lett. 2014 May 15;24(10):2278-82. doi: 10.1016/j.bmcl.2014.03.075. Epub 2014 Apr 3.

PMID:
24726806
25.

Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation.

Furet P, Guagnano V, Fairhurst RA, Imbach-Weese P, Bruce I, Knapp M, Fritsch C, Blasco F, Blanz J, Aichholz R, Hamon J, Fabbro D, Caravatti G.

Bioorg Med Chem Lett. 2013 Jul 1;23(13):3741-8. doi: 10.1016/j.bmcl.2013.05.007. Epub 2013 May 14. Erratum in: Bioorg Med Chem Lett. 2013 Aug 15;23(16):4723.

PMID:
23726034
26.

Enzyme replacement therapy for alpha-mannosidosis: 12 months follow-up of a single centre, randomised, multiple dose study.

Borgwardt L, Dali CI, Fogh J, Månsson JE, Olsen KJ, Beck HC, Nielsen KG, Nielsen LH, Olsen SO, Riise Stensland HM, Nilssen O, Wibrand F, Thuesen AM, Pearl T, Haugsted U, Saftig P, Blanz J, Jones SA, Tylki-Szymanska A, Guffon-Fouiloux N, Beck M, Lund AM.

J Inherit Metab Dis. 2013 Nov;36(6):1015-24. doi: 10.1007/s10545-013-9595-1. Epub 2013 Mar 14.

PMID:
23494656
27.

The lysosomal polypeptide transporter TAPL is stabilized by interaction with LAMP-1 and LAMP-2.

Demirel Ö, Jan I, Wolters D, Blanz J, Saftig P, Tampé R, Abele R.

J Cell Sci. 2012 Sep 15;125(Pt 18):4230-40. doi: 10.1242/jcs.087346. Epub 2012 May 28.

28.

A critical histidine residue within LIMP-2 mediates pH sensitive binding to its ligand β-glucocerebrosidase.

Zachos C, Blanz J, Saftig P, Schwake M.

Traffic. 2012 Aug;13(8):1113-23. doi: 10.1111/j.1600-0854.2012.01372.x. Epub 2012 May 15.

29.

Exploring subtype selectivity and metabolic stability of a novel series of ligands for the benzodiazepine binding site of the GABAA receptor.

Hintermann S, Hurth K, Nozulak J, Tintelnot-Blomley M, Aichholz R, Blanz J, Kaupmann K, Mosbacher J.

Bioorg Med Chem Lett. 2011 Mar 1;21(5):1523-6. doi: 10.1016/j.bmcl.2010.12.107. Epub 2010 Dec 28.

PMID:
21277199
30.

Benzimidazoles as Potent and Orally Active mGlu5 Receptor Antagonists with an Improved PK Profile.

Carcache D, Vranesic I, Blanz J, Desrayaud S, Fendt M, Glatthar R.

ACS Med Chem Lett. 2010 Nov 2;2(1):58-62. doi: 10.1021/ml100215b. eCollection 2011 Jan 13.

31.

Cerebellar alterations and gait defects as therapeutic outcome measures for enzyme replacement therapy in α-mannosidosis.

Damme M, Stroobants S, Walkley SU, Lüllmann-Rauch R, D'Hooge R, Fogh J, Saftig P, Lübke T, Blanz J.

J Neuropathol Exp Neurol. 2011 Jan;70(1):83-94. doi: 10.1097/NEN.0b013e31820428fa.

32.

Lysosomal membrane proteins: life between acid and neutral conditions.

Saftig P, Schröder B, Blanz J.

Biochem Soc Trans. 2010 Dec;38(6):1420-3. doi: 10.1042/BST0381420.

PMID:
21118100
33.

No evidence for a role of CLCN2 variants in idiopathic generalized epilepsy.

Niemeyer MI, Cid LP, Sepúlveda FV, Blanz J, Auberson M, Jentsch TJ.

Nat Genet. 2010 Jan;42(1):3. doi: 10.1038/ng0110-3. No abstract available.

PMID:
20037607
34.

Disease-causing mutations within the lysosomal integral membrane protein type 2 (LIMP-2) reveal the nature of binding to its ligand beta-glucocerebrosidase.

Blanz J, Groth J, Zachos C, Wehling C, Saftig P, Schwake M.

Hum Mol Genet. 2010 Feb 15;19(4):563-72. doi: 10.1093/hmg/ddp523. Epub 2009 Nov 20.

PMID:
19933215
35.

Role for LAMP-2 in endosomal cholesterol transport.

Schneede A, Schmidt CK, Hölttä-Vuori M, Heeren J, Willenborg M, Blanz J, Domanskyy M, Breiden B, Brodesser S, Landgrebe J, Sandhoff K, Ikonen E, Saftig P, Eskelinen EL.

J Cell Mol Med. 2011 Feb;15(2):280-95. doi: 10.1111/j.1582-4934.2009.00973.x.

36.

Reversal of peripheral and central neural storage and ataxia after recombinant enzyme replacement therapy in alpha-mannosidosis mice.

Blanz J, Stroobants S, Lüllmann-Rauch R, Morelle W, Lüdemann M, D'Hooge R, Reuterwall H, Michalski JC, Fogh J, Andersson C, Saftig P.

Hum Mol Genet. 2008 Nov 15;17(22):3437-45. doi: 10.1093/hmg/ddn237. Epub 2008 Aug 19.

PMID:
18713755
37.

Array-based gene discovery with three unrelated subjects shows SCARB2/LIMP-2 deficiency causes myoclonus epilepsy and glomerulosclerosis.

Berkovic SF, Dibbens LM, Oshlack A, Silver JD, Katerelos M, Vears DF, Lüllmann-Rauch R, Blanz J, Zhang KW, Stankovich J, Kalnins RM, Dowling JP, Andermann E, Andermann F, Faldini E, D'Hooge R, Vadlamudi L, Macdonell RA, Hodgson BL, Bayly MA, Savige J, Mulley JC, Smyth GK, Power DA, Saftig P, Bahlo M.

Am J Hum Genet. 2008 Mar;82(3):673-84. doi: 10.1016/j.ajhg.2007.12.019. Epub 2008 Feb 28.

38.

LIMP-2 is a receptor for lysosomal mannose-6-phosphate-independent targeting of beta-glucocerebrosidase.

Reczek D, Schwake M, Schröder J, Hughes H, Blanz J, Jin X, Brondyk W, Van Patten S, Edmunds T, Saftig P.

Cell. 2007 Nov 16;131(4):770-83.

39.

Leukoencephalopathy upon disruption of the chloride channel ClC-2.

Blanz J, Schweizer M, Auberson M, Maier H, Muenscher A, Hübner CA, Jentsch TJ.

J Neurosci. 2007 Jun 13;27(24):6581-9.

40.

Structural determinants of M-type KCNQ (Kv7) K+ channel assembly.

Schwake M, Athanasiadu D, Beimgraben C, Blanz J, Beck C, Jentsch TJ, Saftig P, Friedrich T.

J Neurosci. 2006 Apr 5;26(14):3757-66.

41.

Role of LAMP-2 in lysosome biogenesis and autophagy.

Eskelinen EL, Illert AL, Tanaka Y, Schwarzmann G, Blanz J, Von Figura K, Saftig P.

Mol Biol Cell. 2002 Sep;13(9):3355-68.

42.

Accumulation of autophagic vacuoles and cardiomyopathy in LAMP-2-deficient mice.

Tanaka Y, Guhde G, Suter A, Eskelinen EL, Hartmann D, Lüllmann-Rauch R, Janssen PM, Blanz J, von Figura K, Saftig P.

Nature. 2000 Aug 24;406(6798):902-6.

PMID:
10972293
43.

Use of a water-soluble busulfan formulation--pharmacokinetic studies in a canine model.

Ehninger G, Schuler U, Renner U, Ehrsam M, Zeller KP, Blanz J, Storb R, Deeg HJ.

Blood. 1995 Jun 1;85(11):3247-9.

PMID:
7756656
44.

Biotransformation of CI-937 in primary cultures of rat hepatocytes. Formation of glutathione conjugates.

Renner U, Blanz J, Freund S, Waidelich D, Ehninger G, Zeller KP.

Drug Metab Dispos. 1995 Jan;23(1):94-101.

PMID:
7720531
45.

Busulfan pharmacokinetics in bone marrow transplant patients: is drug monitoring warranted?

Schuler U, Schroer S, Kühnle A, Blanz J, Mewes K, Kumbier I, Proksch B, Zeller KP, Ehninger G.

Bone Marrow Transplant. 1994 Nov;14(5):759-65.

PMID:
7889009
46.

Detection and separation of the anthrapyrazole CI-941 and its metabolites in serum and urine by high-performance liquid chromatography.

Proksch B, Blanz J, Zeller KP, Ehninger G.

J Chromatogr B Biomed Appl. 1994 Aug 19;658(2):349-53.

PMID:
7820263
47.

Synthesis and structural elucidation of biliary excreted thioether derivatives of mitoxantrone.

Mewes K, Blanz J, Freund S, Ehninger G, Zeller KP.

Xenobiotica. 1994 Mar;24(3):199-213.

PMID:
8009883
48.

Cytochrome P-450-induced cytotoxicity of mitoxantrone by formation of electrophilic intermediates.

Mewes K, Blanz J, Ehninger G, Gebhardt R, Zeller KP.

Cancer Res. 1993 Nov 1;53(21):5135-42.

49.

Detection and identification of human urinary metabolites of biantrazole (CI-941).

Blanz J, Renner U, Schmeer K, Ehninger G, Zeller KP.

Drug Metab Dispos. 1993 Sep-Oct;21(5):955-61.

PMID:
7902262
50.

Evidence for oxidative activation of mitoxantrone in human, pig, and rat.

Blanz J, Mewes K, Ehninger G, Proksch B, Waidelich D, Greger B, Zeller KP.

Drug Metab Dispos. 1991 Sep-Oct;19(5):871-80.

PMID:
1686230

Supplemental Content

Support Center